echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Acta Neuropathologica: Under-the-scenes C11orf95 fusion gliomas and on-screen RELA fusion chamber membrane tumors share histology, immunomoral and molecular characteristics

    Acta Neuropathologica: Under-the-scenes C11orf95 fusion gliomas and on-screen RELA fusion chamber membrane tumors share histology, immunomoral and molecular characteristics

    • Last Update: 2020-12-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cervosarcoma is a group of heterogeneous gliomas that occur in different parts of the central nervous system and exhibit a wide range of tissue pathological characteristics.
    DNA methyl group analysis and transcription group analysis have identified at least 9 groups of cerial melanoma molecules separated by anatomical positions and molecular changes.
    on-screen tube melanoma is characterized by gene fusion that contains RELA or YAP1.
    there are two main types of post-cranial den (PF) cytoblastoma: PFA occurs in young children with poor prognosis, while PFB occurs in older children and adults, and the prognosis is better.
    has so far been observed to have C11orf95 RELA fused PF chamber membrane tumors, although they are located under the curtain, it is not clear whether they represent an obvious subtype of cervirine melanoma, or closely related to ST RELA fusion chamber membrane tumors.
    This paper found that the tissue pathology characteristics of three sub-scene gliomas (one cervical myelin and two small brains) were very similar to ST-RELA fusion chamber meningiomas: all tumors were non-immersive growths with different edges than adjacent cervical or spinal cord tissue.
    cytology and structure of the same tumor vary, but microcalcification of a single tumor cell group, cytostyte clarity, ringless bands around blood vessels, and malnutrition are consistent characteristics.
    myelin tumor also shows the growth of the nipple-like condition.
    the silk splitting activity is obvious, and the Ki-67 marker is high in all tumors, proving a high level of marking.
    all tumors are characterized by st-RELA fusion chamber membrane tumors -- there is a variable GFAP immune response.
    Oleg2 and Sox10 are occasionally expressed in cells.
    L1CAM was strongly diffuse and positive in all tumors, and histoprotein H3 K27 residual trimethylation retained nuclear immune response.
    : Fluorescence in-place hybridization (FISH) identified the rearfraction of C11orf95 and RELA in 2 (cases 2 and 3) and 1 (case 3) tumors, respectively.
    RNA sequence analysis, we found C11orf95-MAML2, C11orf95-NCOA2, and C11orf95-related fusions in these tumors.
    found C11orf95-MAML2 and C11orf95-related fusions in ST-room tube melanomas, and C11orf95-NCOA2 fusion is a new discovery.
    with the exception of the BCOR V406fs subclonal variant with an allequential gene frequency of 8% in case 3, the per exon sequencing of all tumors was negative.
    fish did not detect an increase in chromosomal arm 1q, adverse prognostofic factors for PFA and PFB, and the absence of CDKN2A/B.
    : Studies have shown that RELA-fused tracheal melanomas do not require fusion transcription involving RELA to produce pathological histology and molecular markers.
    the discovery of this paper broadens the scope of C11orf95 fusion chamber membrane tumor, and has guiding significance for the diagnosis and classification of cervosa tumor.
    Keenan, C., Graham, R.T., Harreld, J.H. et al. Infratentorial C11orf95-fused gliomas share histologic, immunophenotypic, and molecular characteristics of supratentorial RELA-fused ependymoma. Acta Neuropathol 140, 963–965 (2020). MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.